Patients were required to discontinue all systemic immunosuppressants other than corticosteroids 30 days prior to the first study drug administration at baseline.
For all scales, the time for administration at baseline and at week 12 remained constant by severity stage and overall (Table 4).
Questionnaire 3 has two versions in order to try and reduce respondent burden: version "a" for administration at baseline, and version "b" for sequential administration thereafter.
Two versions of the anagram task were developed and piloted for administration at baseline and test with difficulty level matched across versions.
For measurement of bone turnover markers, serum and urine samples were taken before teriparatide administration at baseline, at 1 week after administration, and at 4, 12, 24, 48 and 72 weeks under non-fasting conditions.
Blood samples were collected from a catheter placed in the arm opposite of 99mTc mebrofenin administration at baseline, and at designated time points up to 180 min after administration of the 99mTc mebrofenin dose.
The serum prolactin level was significantly lower after APZ administration than at baseline, and it was also significantly lower in the APZ group than in the placebo group in the randomized, double-blinded, placebo-controlled trials for schizophrenia [ 34], bipolar type I disorder [ 30], and autism [ 31, 37].
Blood samples were collected at regular intervals over 10 h before and after the MMF administration (at the baseline and after 1, 2, 3, 4, 6, 8, and 10 h).
None of the other clinical covariates investigated (route of administration, creatinine clearance at baseline, indices of liver status, and concomitant medications) showed a statistically significant effect on panobinostat PK.
To evaluate the single-agent PK of sirolimus, blood samples were obtained at 15 time points for up to 4 days after the first administration, as follows: at baseline, 20 and 40 min, and at 1, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48, 72 and 96 h after the first administration on day 1.
Simulations based on the integrated ocular/systemic TMDD PK model were performed to predict the ratio of free target (FTR) following lampalizumab administration to that at baseline (FTR = free target/total target at baseline) in the vitreous humor to aid in dosing selection for future clinical studies.
